**Supplementary Fig. S1** Adimin1 by modified CWA in FVIII-deficient plasma in the presence of various rFVIII and emicizumab—various rFVIII (panel A); B-domainless rFVIII, panel (B); rFVIIIFc, panel (C); plasma-derived FVIII/ von Willebrand factor complex) and emicizumab were added to FVIII-deficient plasmas and incubated with PT/aPTT mixture reagent prior to the addition of CaCl2 in the adjusted-CWA as described in methods. The Adimin1 derived from adjusted clot waveforms in each sample were plotted as a function of emicizumab. The gray bar represents the normal reference (mean ± standard deviation; 7.22 ± 0.21) of Adimin1 from healthy individuals (n = 20, NP). The concentrations of FVIII shown in (A–C) represent; 0 IU/dL; open circles, 5 IU/dL; closed circles, 20 IU/dL; open squares, 40 IU/dL; closed squares. aPPT, activated partial thromboplastin time; CWA, clot waveform analysis.